Matthias Eiber

Jan 17, 2025 | nature.com | Matthias Eiber

AbstractProstate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing 18F-rhPSMA-7 or 18F-flotufolastat (18F-rhPSMA-7.3)-PET-guided SRT compared with conventional-SRT (C-SRT) without PET.

Feb 9, 2024 | urotoday.com | Matthias Eiber

Read the Full Video TranscriptMatthias Eiber: Thanks, Jeremie, for the introduction at the beginning of the session. And Johannes, Tom, and Jeremie, thanks for inviting me to this wonderful meeting here.

Jul 5, 2023 | europeanurology.com | Matthias Eiber |Tobias Maurer |Mark Preston |Brian Helfand

AbstractRadiohybrid (rh) 18F-rhPSMA-7.3 is a novel high-affinity prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) imaging. To evaluate the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed PCa patients planned for prostatectomy. Data on 18F-rhPSMA-7.3 were reported from the phase 3 prospective, multicentre LIGHTHOUSE study (NCT04186819).